Cargando…

Editorial: Epigenetic Modifications in Mesothelioma

Detalles Bibliográficos
Autores principales:	Cheng, Yuen Yee, Yuen, Man Lee, Jin, Hongchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887309/ https://www.ncbi.nlm.nih.gov/pubmed/33614517 http://dx.doi.org/10.3389/fonc.2021.650136

Ejemplares similares

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Preclinical Models and Resources to Facilitate Basic Science Research on Malignant Mesothelioma – A Review
por: Johnson, Ben William, et al.
Publicado: (2021)

Editorial: The Role of Epigenetic Modifications in Cancer Progression
por: Fujimura, Atsushi, et al.
Publicado: (2021)

Editorial: The interconnection between epigenetic modifications and the tumor microenvironment
por: He, Siyuan, et al.
Publicado: (2023)

CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation
por: Cheng, Yuen Yee, et al.
Publicado: (2020)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Editorial: Altered epigenetic modification mediated dysregulated transcriptional networks in drug resistance
por: Brunetti, Bryce, et al.
Publicado: (2023)

Leptospermum extract (QV0) suppresses pleural mesothelioma tumor growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis
por: Shi, Huaikai, et al.
Publicado: (2023)

SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2017)

Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application
por: Lin, Hon-Yi, et al.
Publicado: (2023)

3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies
por: Shi, Huaikai, et al.
Publicado: (2022)

Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
por: Ferrari, Luca, et al.
Publicado: (2020)

Exploring MicroRNA and Exosome Involvement in Malignant Pleural Mesothelioma Drug Response
por: Johnson, Ben, et al.
Publicado: (2022)

Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2023)

Editorial: Epigenetics in prostate cancer
por: Baniahmad, Aria, et al.
Publicado: (2023)

The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
por: Cheng, Yuen Yee, et al.
Publicado: (2020)

Editorial: Mechanisms of Epigenetics and Genetics in Leukemogenesis
por: Li, Yonghui, et al.
Publicado: (2022)

Editorial: Epigenetic Regulation and Tumor Immunotherapy
por: Sun, Hongyin, et al.
Publicado: (2022)

Editorial: Epigenetics and cellular plasticity in glioblastoma
por: Lo, Hui-Wen, et al.
Publicado: (2023)

Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy
por: Tomasetti, Marco, et al.
Publicado: (2019)

Interaction of ncRNA and Epigenetic Modifications in Gastric Cancer: Focus on Histone Modification
por: Yang, Qingfan, et al.
Publicado: (2022)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Editorial: Epigenetics and molecular genetics of rare tumors
por: Tognon, Mauro, et al.
Publicado: (2022)

Editorial: Epigenetic insights into diagnostic and therapeutic applications
por: Fratta, Elisabetta, et al.
Publicado: (2023)

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
por: Cavallari, Ilaria, et al.
Publicado: (2023)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
por: Dhall, Abhinav, et al.
Publicado: (2019)

Editorial: Epigenetic and metabolic regulation of primary and metastatic brain cancers
por: Gimple, Ryan C., et al.
Publicado: (2023)

Editorial: Genetic/epigenetic mechanisms and related clinical strategy in leukemia
por: Li, Yonghui, et al.
Publicado: (2023)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Development and Validation of Epigenetic Modification-Related Signals for the Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Lu, Maoqing, et al.
Publicado: (2021)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

Editorial: RNA and RNA modification in the pathogenesis, diagnosis and treatment of cancers
por: Wang, Lihui, et al.
Publicado: (2022)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Emerging roles of interactions between ncRNAs and other epigenetic modifications in breast cancer
por: Xie, Junyuan, et al.
Publicado: (2023)

Genomics and Epigenetics of Malignant Mesothelioma
por: Sage, Adam P., et al.
Publicado: (2018)

The Use of Epigenetic Biomarkers as Diagnostic and Therapeutic Options
por: Zhang, Le, et al.
Publicado: (2022)

Epigenetic Biomarkers in Cancer
por: Cheng, Yuen Yee, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1vql24r1t6osvcdod9eccu4k6t